| abstract |
The present invention refers to a formulation for intrathecal administration comprising a human recombinant arylsulfatase A (ASA) protein at a concentration ranging from 5-300 mg / ml, salt to a concentration of 0-300 mM, a polysorbate surfactant a a concentration of 0-0.2% and phosphate at a concentration no greater than 50 mM; being useful in the treatment of lysosomal storage diseases, such as Metachromatic Leukodystrophy Disease |